Picture of Biosyent logo

RX — Biosyent Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareBalancedSmall CapSuper Stock

Momentum

Relative Strength (%)
1m+6.72%
3m-1.05%
6m+6.32%
1yr-0.42%
Volume Change (%)
10d/3m+76.1%
Price vs... (%)
52w High-22%
50d MA-7.13%
200d MA-4.05%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)14.05
PEG Ratio (f)2.17
EPS Growth (f)6.92%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.07
Price to Tang. Book3.16
Price to Free Cashflow18.28
Price to Sales3.48
EV to EBITDA8.58

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital24.05%
Return on Equity20.76%
Operating Margin28.59%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total RevenueCA$m20.7621.5321.4222.3328.6230.132.39.81%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+21.09+10.05-9.12-19.44+68.37+12.7+1.82n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for RX

Two reasons to look twice at Biosyent (CVE:RX) background image

Two reasons to look twice at Biosyent (CVE:RX)

The Biosyent (CVE:RX) share price is currently trading at C$8.36. But given the uncertain economic outlook, the question now is what the future holds for it. To try and predict where the Biosyent price will head next, it's worth knowin...

Four clues to the quality of Biosyent Inc (CVE:RX) background image

Four clues to the quality of Biosyent Inc (CVE:RX)

Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that these stocks are hard to find - but there are signs that Biosyent Inc CVE:RX...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biosyent EPS forecast chart

Profile Summary

BioSyent Inc. (BioSyent) is a Canada-based specialty pharmaceutical company. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
May 19th, 1999
Public Since
May 22nd, 1981
No. of Employees
0
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
12,614,661

RX Share Price Performance

Upcoming Events for RX

Q2 2022 Biosyent Inc Earnings Release

Q3 2022 Biosyent Inc Earnings Release

Similar to RX

Picture of Acasti Pharma logo

Acasti Pharma

ca flag iconTSX Venture Exchange

Picture of Aequus Pharmaceuticals logo

Aequus Pharmaceuticals

ca flag iconTSX Venture Exchange

Picture of Avricore Health logo

Avricore Health

ca flag iconTSX Venture Exchange

Picture of Cannara Biotech logo

Cannara Biotech

ca flag iconTSX Venture Exchange

Picture of Decibel Cannabis logo

Decibel Cannabis

ca flag iconTSX Venture Exchange

FAQ

Or unlock with your email

Or unlock with your email